Lexeo Therapeutics, Inc. 8-K

What Happened
Lexeo Therapeutics, Inc. announced on March 30, 2026 that it issued a press release with business highlights and its financial results for the three and twelve months ended December 31, 2025. The press release is furnished as Exhibit 99.1 to the Company’s Form 8‑K. On the same date the company posted an updated corporate presentation (Exhibit 99.2) that it will use in investor and analyst meetings. The filing was signed by CEO R. Nolan Townsend.

Key Details

• Filing date: March 30, 2026 (Form 8‑K items 2.02 and 8.01).
• Reporting period: three and twelve months ended December 31, 2025 (quarterly and full‑year results).
• Exhibits provided: Exhibit 99.1 — press release (financial results/business highlights); Exhibit 99.2 — updated corporate presentation dated March 30, 2026.
• Signed by: R. Nolan Townsend, Chief Executive Officer.

Why It Matters
This 8‑K notifies investors that Lexeo has released its latest quarterly and full‑year earnings and related business updates; the press release and corporate presentation are the primary sources for detailed earnings, revenue, expense, and operational metrics. Retail investors should review the attached press release and presentation for the specific financial figures and guidance, as these items can affect short‑term stock reactions and longer‑term valuation.